.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Cantor Fitzgerald
Federal Trade Commission
Boehringer Ingelheim
Baxter
Covington
Chinese Patent Office
Dow
Novartis

Generated: September 26, 2017

DrugPatentWatch Database Preview

DILAUDID Drug Profile

« Back to Dashboard

What is the patent landscape for Dilaudid, and what generic Dilaudid alternatives are available?

Dilaudid is a drug marketed by Fresenius Kabi Usa and Rhodes Pharms and is included in three NDAs. There is one patent protecting this drug and four Paragraph IV challenges.

This drug has seventeen patent family members in nine countries.

The generic ingredient in DILAUDID is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.

Summary for Tradename: DILAUDID

Patents:1
Applicants:2
NDAs:3
Suppliers / Packagers: see list8
Bulk Api Vendors: see list8
Clinical Trials: see list71
Patent Applications: see list5,084
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DILAUDID at DailyMed

Pharmacology for Tradename: DILAUDID

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-003Apr 30, 2009APRXYesYes► Subscribe► SubscribeYY ► Subscribe
Rhodes Pharms
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL019892-001Dec 7, 1992ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Rhodes Pharms
DILAUDID
hydromorphone hydrochloride
SOLUTION;ORAL019891-001Dec 7, 1992AARXYesYes► Subscribe► SubscribeYY ► Subscribe
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-001Jan 11, 1984APRXYesYes► Subscribe► SubscribeY ► Subscribe
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-004Apr 30, 2009APRXYesYes► Subscribe► SubscribeYY ► Subscribe
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-005Apr 30, 2009APRXYesYes► Subscribe► SubscribeYY ► Subscribe
Rhodes Pharms
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL019892-002Nov 9, 2007ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Rhodes Pharms
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL019892-003Nov 9, 2007ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-002Aug 4, 1994DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for DILAUDID

Drugname Dosage Strength RLD Submissiondate
hydromorphone hydrochlorideInjection2 mg/mLDilaudid6/22/2011
hydromorphone hydrochlorideInjection10 mg/mLDilaudid-HP11/4/2011
hydromorphone hydrochlorideOral Solution5 mg/5mLDilaudid2/25/2011
hydromorphone hydrochlorideTablets2 mg, 4 mg, and 8 mgDilaudid8/5/2013

Non-Orange Book Patents for Tradename: DILAUDID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DILAUDID

Country Document Number Estimated Expiration
Germany60045695► Subscribe
Spain2359657► Subscribe
European Patent Office2003134► Subscribe
Germany60039711► Subscribe
Austria500257► Subscribe
Canada2389193► Subscribe
Japan2003513980► Subscribe
Australia1595701► Subscribe
European Patent Office2338891► Subscribe
Japan4886953► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Army
QuintilesIMS
McKinsey
Covington
Citi
Merck
Moodys
Cerilliant
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot